Grindeks

Ettevõttest

Name: AS "Grindeks”
Core business: Pharmaceuticals manufacturing
Auditor: SIA „Deloitte Audits Latvia”
Date of listing: 01.06.1998.- 01.01.2006 I-list
                        From 02.01.2006 Main list 
Market: Nasdaq Riga

Supervisory Board:
Kirovs Lipmans (Chairman), Anna Lipmane, Jānis Naglis, Arkadiy Vertkin

Management Board: 
Juris Bundulis (Chairman), Jānis Romanovskis

 

Background information
“Grindeks” is an international, vertically integrated pharmaceutical company in the Baltics States. Main fields of action are research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. The Group of “Grindeks” consists of five subsidiary companies in Latvia, Estonia, Russia and Slovakia, as well as representative offices in 12 countries.

“Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur®. Currently “Grindeks” produces 23 active pharmaceutical ingredients.

Products of the company are exported to 71 countries and its export comprises 91% of the total turnover. The key markets include the EU countries, Russia and other CIS countries, the U.S., Canada, Japan and Vietnam.

AS “Grindeks” shares are listed in the Official List of “NASDAQ Riga”.

“Grindeks” Active pharmaceutical ingredients and Final dosage forms plants have received Good Manufacturing Practice (GMP) certificates, while company’s achievements in the Integrated Quality management, Environmental and Energy management, Occupational Health and Safety Management system are approved by ISO 9001, ISO 14001, ISO 50001, ISO 17025 un OHSAS 18001 certificates, as well as successfully performed supervisory audits.

In 2002, as one of the first companies in Latvia “Grindeks” joined the UN Global Compact movement. Since then, certifying loyalty to its core principles, “Grindeks” has performed the Corporate Social Responsibility in four main directions – patient, society, employee, as well as quality and environmental protection.

To increase production capacity and develop infrastructure, the company has accomplished many significant investment projects, investing more than 90 million euros over the last 15 years.

To achieve company’s strategic business objectives, priorities for 2017 are:

  • strategic business development markets - European Union and Southeast Asia countries;
  • planned sales growth in the European Union and Southeast Asia countries +30%;
  • strengthening positions in Russia and other CIS countries;
  • expansion of AS "Kalceks" activities;
  • optimization of current assets and cost reduction in positions unrelated to the strategic development projects, as well as product registration and progress.


Corporate Social Responsibility

AS "Grindeks" Corporate Social Responsibility Report 2009
AS "Grindeks" Corporate Social Responsibility Report 2010
AS "Grindeks" Corporate Social Responsibility Report 2011
AS "Grindeks" Corporate Social Responsibility Report 2012
AS "Grindeks" Corporate Social Responsibility Report 2013
AS "Grindeks" Corporate Social Responsibility Report 2014
AS "Grindeks" Corporate Social Responsibility Report 2015
AS "Grindeks" Corporate Social Responsibility Report 2016

Informative materials

Virtual tour of "Grindeks"

Contacts:
Address: 53 Krustpils str, Riga, LV-1057
Phone: + 371 67083500
Fax: + 371 67083505
Internet: www.grindeks.lv  
E-mail: grindeks@grindeks.lv  

Contactperson: Agita Baranovska
Phone: + 371 67083252
E-mail: agita.baranovska@grindeks.lv


Emitendi dokumendid

Sündmuse tüüp Dokumendi kuupäev Dokumendid
Kauplemisele võtmine 2011, November Prospectus for closed share listing – LV (1,8 MB)
Kauplemisele võtmine 2005, Mai Prospectus for listing of additionally issued shares – LV (1,9 MB)
Terms of share capital increase – EN (104,9 KB)
Terms of share capital increase – LV (261,3 KB)
Kauplemisele võtmine 2001, Oktoober Initial admission prospectus – LV (1,7 MB)